1
NR 546 MIDTERM 100 EXAM – ADVANCED PSYCHOPHARMACOLOGY
– CHAMBERLAIN UNIVERSITY – 2026/2027 ACADEMIC YEAR] ACTUAL
QUESTIONS AND CORRECT ANSWERS (VERIFIED ANSWERS) PLUS
RATIONALES 2026 Q&A | INSTANT DOWNLOAD PDF
Core Domains
Neurobiology and Receptor Pharmacology
Pharmacokinetics and Pharmacodynamics in Psychiatric Medications
Antidepressants and Mood Stabilizers
Antipsychotics and Neuroleptic Medications
Anxiolytics, Sedatives, and Hypnotics
Psychopharmacology Across the Lifespan
Drug-Drug Interactions and Adverse Effect Management
Legal, Ethical, and Cultural Considerations in Prescribing
Introduction
This assessment rigorously evaluates the advanced psychopharmacology
knowledge essential for Chamberlain University’s NR 546 midterm. It measures
proficiency in neurobiological mechanisms, neurotransmitter systems, and the
clinical application of psychotropic agents for mood, anxiety, psychotic, and other
psychiatric disorders. The multiple-choice format incorporates challenging
scenario-based questions that mirror complex clinical decision-making, requiring
integration of pathophysiology, medication selection, side-effect management,
and legal/ethical prescribing practices. Each item is crafted to test not only recall
of pharmacologic principles but also the critical thinking necessary for safe,
effective, and culturally competent psychiatric care. Thorough rationales
accompany every answer, reinforcing core concepts and preparing the learner for
high-stakes examination success.
SECTION ONE: Questions 1–50
1. A 34-year-old female with major depressive disorder has been taking
fluoxetine 20 mg daily for 8 weeks with partial response. She reports
pg. 1
,2
persistent fatigue, hypersomnia, and weight gain. The psychiatric-mental
health nurse practitioner (PMHNP) considers adding bupropion XL 150 mg
daily to target residual symptoms. Which pharmacodynamic action of
bupropion is most likely to complement fluoxetine and mitigate these
specific residual symptoms?
A. Serotonin 5-HT2A receptor antagonism and serotonin reuptake inhibition.
B. Norepinephrine-dopamine reuptake inhibition, enhancing noradrenergic and
dopaminergic tone to improve energy and motivation.
C. Norepinephrine-dopamine reuptake inhibition (NDRI), which increases
synaptic norepinephrine and dopamine, counteracting fatigue, hypersomnia, and
weight gain often associated with selective serotonin reuptake inhibitor (SSRI)
treatment.
D. Monoamine oxidase inhibition, increasing all monoamines.
RATIONALE: Bupropion is a norepinephrine-dopamine reuptake inhibitor. Its
enhancement of noradrenergic and dopaminergic transmission can alleviate
symptoms of low energy, hypersomnia, and increased appetite that may persist
or emerge during SSRI monotherapy. Option A describes a serotonin
antagonist/reuptake inhibitor (e.g., trazodone). Option C correctly identifies the
mechanism and the rationale for symptom targeting. Option D refers to MAOIs,
which would be dangerous in combination with an SSRI. Thus, C is the most
precise and clinically appropriate.
2. A 28-year-old male with schizophrenia has been stable on risperidone 4
mg/day. He develops acute severe muscle rigidity, diaphoresis,
hyperthermia (103.1°F), tachycardia, and elevated creatine kinase (CK) to
15,000 U/L. His mental status fluctuates. The most likely diagnosis is
neuroleptic malignant syndrome (NMS). After discontinuing risperidone
and initiating supportive care, which pharmacologic agent is most
specifically recommended to reverse the central dopaminergic blockade?
A. Diphenhydramine 50 mg IV.
B. Lorazepam 2 mg IV.
C. Bromocriptine, a dopamine agonist, to counteract the D2 receptor
blockade underlying NMS.
D. Dantrolene sodium IV for muscle rigidity only.
pg. 2
, 3
RATIONALE: NMS results from acute D2 receptor antagonism leading to
severe extrapyramidal symptoms, autonomic instability, and hyperthermia.
Bromocriptine, a direct dopamine agonist, helps restore dopaminergic
transmission. Dantrolene (D) is a muscle relaxant that may be used adjunctively
for hyperthermia and rigidity but does not directly address the central dopamine
blockade. Diphenhydramine (A) is for acute dystonia, not NMS. Lorazepam (B)
may help with agitation but is not specific. Thus, C is the most targeted
pharmacotherapy.
3. A 45-year-old woman with generalized anxiety disorder has been on
paroxetine 30 mg daily for 6 months. She abruptly stops the medication
and within 3 days develops intense dizziness, nausea, electric shock
sensations, and insomnia. These symptoms are best explained by which
mechanism?
A. Cholinergic rebound due to muscarinic receptor upregulation.
B. Serotonin discontinuation syndrome resulting from rapid decline in
synaptic serotonin and transient downregulation of postsynaptic 5-HT receptors.
C. Dopamine supersensitivity due to chronic SSRI use.
D. Withdrawal from norepinephrine reuptake inhibition.
RATIONALE: Abrupt cessation of an SSRI, especially one with a short half-life
like paroxetine, can cause serotonin discontinuation syndrome. The symptoms—
dizziness, paresthesias, nausea, and flu-like symptoms—are attributed to a rapid
decrease in serotonin availability and temporary receptor dysregulation. Option A
describes anticholinergic rebound (more typical of TCAs). Option C is not a
recognized mechanism for SSRIs. Option D would be more relevant for SNRIs. So B
is correct.
4. A 72-year-old male with vascular dementia exhibits severe agitation,
impulsivity, and psychotic features. The PMHNP considers using an
antipsychotic but must be cautious due to the FDA black box warning.
Which medication is associated with the highest risk of cerebrovascular
adverse events and mortality in elderly patients with dementia-related
psychosis?
pg. 3
NR 546 MIDTERM 100 EXAM – ADVANCED PSYCHOPHARMACOLOGY
– CHAMBERLAIN UNIVERSITY – 2026/2027 ACADEMIC YEAR] ACTUAL
QUESTIONS AND CORRECT ANSWERS (VERIFIED ANSWERS) PLUS
RATIONALES 2026 Q&A | INSTANT DOWNLOAD PDF
Core Domains
Neurobiology and Receptor Pharmacology
Pharmacokinetics and Pharmacodynamics in Psychiatric Medications
Antidepressants and Mood Stabilizers
Antipsychotics and Neuroleptic Medications
Anxiolytics, Sedatives, and Hypnotics
Psychopharmacology Across the Lifespan
Drug-Drug Interactions and Adverse Effect Management
Legal, Ethical, and Cultural Considerations in Prescribing
Introduction
This assessment rigorously evaluates the advanced psychopharmacology
knowledge essential for Chamberlain University’s NR 546 midterm. It measures
proficiency in neurobiological mechanisms, neurotransmitter systems, and the
clinical application of psychotropic agents for mood, anxiety, psychotic, and other
psychiatric disorders. The multiple-choice format incorporates challenging
scenario-based questions that mirror complex clinical decision-making, requiring
integration of pathophysiology, medication selection, side-effect management,
and legal/ethical prescribing practices. Each item is crafted to test not only recall
of pharmacologic principles but also the critical thinking necessary for safe,
effective, and culturally competent psychiatric care. Thorough rationales
accompany every answer, reinforcing core concepts and preparing the learner for
high-stakes examination success.
SECTION ONE: Questions 1–50
1. A 34-year-old female with major depressive disorder has been taking
fluoxetine 20 mg daily for 8 weeks with partial response. She reports
pg. 1
,2
persistent fatigue, hypersomnia, and weight gain. The psychiatric-mental
health nurse practitioner (PMHNP) considers adding bupropion XL 150 mg
daily to target residual symptoms. Which pharmacodynamic action of
bupropion is most likely to complement fluoxetine and mitigate these
specific residual symptoms?
A. Serotonin 5-HT2A receptor antagonism and serotonin reuptake inhibition.
B. Norepinephrine-dopamine reuptake inhibition, enhancing noradrenergic and
dopaminergic tone to improve energy and motivation.
C. Norepinephrine-dopamine reuptake inhibition (NDRI), which increases
synaptic norepinephrine and dopamine, counteracting fatigue, hypersomnia, and
weight gain often associated with selective serotonin reuptake inhibitor (SSRI)
treatment.
D. Monoamine oxidase inhibition, increasing all monoamines.
RATIONALE: Bupropion is a norepinephrine-dopamine reuptake inhibitor. Its
enhancement of noradrenergic and dopaminergic transmission can alleviate
symptoms of low energy, hypersomnia, and increased appetite that may persist
or emerge during SSRI monotherapy. Option A describes a serotonin
antagonist/reuptake inhibitor (e.g., trazodone). Option C correctly identifies the
mechanism and the rationale for symptom targeting. Option D refers to MAOIs,
which would be dangerous in combination with an SSRI. Thus, C is the most
precise and clinically appropriate.
2. A 28-year-old male with schizophrenia has been stable on risperidone 4
mg/day. He develops acute severe muscle rigidity, diaphoresis,
hyperthermia (103.1°F), tachycardia, and elevated creatine kinase (CK) to
15,000 U/L. His mental status fluctuates. The most likely diagnosis is
neuroleptic malignant syndrome (NMS). After discontinuing risperidone
and initiating supportive care, which pharmacologic agent is most
specifically recommended to reverse the central dopaminergic blockade?
A. Diphenhydramine 50 mg IV.
B. Lorazepam 2 mg IV.
C. Bromocriptine, a dopamine agonist, to counteract the D2 receptor
blockade underlying NMS.
D. Dantrolene sodium IV for muscle rigidity only.
pg. 2
, 3
RATIONALE: NMS results from acute D2 receptor antagonism leading to
severe extrapyramidal symptoms, autonomic instability, and hyperthermia.
Bromocriptine, a direct dopamine agonist, helps restore dopaminergic
transmission. Dantrolene (D) is a muscle relaxant that may be used adjunctively
for hyperthermia and rigidity but does not directly address the central dopamine
blockade. Diphenhydramine (A) is for acute dystonia, not NMS. Lorazepam (B)
may help with agitation but is not specific. Thus, C is the most targeted
pharmacotherapy.
3. A 45-year-old woman with generalized anxiety disorder has been on
paroxetine 30 mg daily for 6 months. She abruptly stops the medication
and within 3 days develops intense dizziness, nausea, electric shock
sensations, and insomnia. These symptoms are best explained by which
mechanism?
A. Cholinergic rebound due to muscarinic receptor upregulation.
B. Serotonin discontinuation syndrome resulting from rapid decline in
synaptic serotonin and transient downregulation of postsynaptic 5-HT receptors.
C. Dopamine supersensitivity due to chronic SSRI use.
D. Withdrawal from norepinephrine reuptake inhibition.
RATIONALE: Abrupt cessation of an SSRI, especially one with a short half-life
like paroxetine, can cause serotonin discontinuation syndrome. The symptoms—
dizziness, paresthesias, nausea, and flu-like symptoms—are attributed to a rapid
decrease in serotonin availability and temporary receptor dysregulation. Option A
describes anticholinergic rebound (more typical of TCAs). Option C is not a
recognized mechanism for SSRIs. Option D would be more relevant for SNRIs. So B
is correct.
4. A 72-year-old male with vascular dementia exhibits severe agitation,
impulsivity, and psychotic features. The PMHNP considers using an
antipsychotic but must be cautious due to the FDA black box warning.
Which medication is associated with the highest risk of cerebrovascular
adverse events and mortality in elderly patients with dementia-related
psychosis?
pg. 3
